Eidos Therapeutics, Inc. Common Stock
EIDX
EIDX was delisted on the 25th of January, 2021.
78 hedge funds and large institutions have $418M invested in Eidos Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 17 increasing their positions, 27 reducing their positions, and 3 closing their positions.
567% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 3
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
25% more capital invested
Capital invested by funds: $334M → $418M (+$83.1M)
24% more funds holding
Funds holding: 63 → 78 (+15)
37% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$7.76M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.47M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
+$2.98M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.86M |
| 5 |
EU
Emory University
Atlanta,
Georgia
|
+$2.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$29.9M |
| 2 |
BlackRock
New York
|
-$6.63M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$3.18M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.77M |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$2.17M |
EIDX Hedge Fund Activity: Q2 2019 in Review
78 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Eidos Therapeutics, Inc. Common Stock (EIDX) for Q2 2019, worth a combined $418M — up 25% from $334M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new EIDX positions and 3 closed out — a net gain of 17 holders — while 17 added to existing stakes and 27 trimmed.
The largest buyer was Lord, Abbett & Co, adding an estimated $7.76M. The largest seller was Viking Global Investors, cutting an estimated $29.9M.
- 78 institutional investors held Eidos Therapeutics, Inc. Common Stock (EIDX) as of Q2 2019, up from 63 in Q1 2019.
- Funds reported $418M of Eidos Therapeutics, Inc. Common Stock stock for Q2 2019, up 25% quarter-over-quarter.
- 20 funds opened new Eidos Therapeutics, Inc. Common Stock positions in Q2 2019 and 3 closed out, a net change of +17 holders.
- The largest Eidos Therapeutics, Inc. Common Stock buyer in Q2 2019 was Lord, Abbett & Co, an estimated $7.76M added.
- The largest Eidos Therapeutics, Inc. Common Stock seller in Q2 2019 was Viking Global Investors, an estimated $29.9M sold.
Based on aggregated 13F filings for Q2 2019.